80 related articles for article (PubMed ID: 21291797)
1. The role of lipoprotein-associated phospholipase A2 on cardiovascular disease risk assessment and plaque rupture: a clinical review.
Reddy KJ; Singh M; Bangit JR; Batsell RR
J Clin Lipidol; 2009 Apr; 3(2):85-93. PubMed ID: 21291797
[TBL] [Abstract][Full Text] [Related]
2. Identifying the vulnerable patient with rupture-prone plaque.
Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):3F-10F. PubMed ID: 18549869
[TBL] [Abstract][Full Text] [Related]
3. Review of the evidence for the clinical utility of lipoprotein-associated phospholipase A2 as a cardiovascular risk marker.
Corson MA; Jones PH; Davidson MH
Am J Cardiol; 2008 Jun; 101(12A):41F-50F. PubMed ID: 18549871
[TBL] [Abstract][Full Text] [Related]
4. [Does Lp-PLA2 determination help predict atherosclerosis and cardiocerebrovascular disease?].
Sertić J; Skorić B; Lovrić J; Bozina T; Reiner Z
Acta Med Croatica; 2010 Oct; 64(4):237-45. PubMed ID: 21688606
[TBL] [Abstract][Full Text] [Related]
5. Lipoprotein-associated phospholipase A(2): a promising vascular-specific marker for screening cardiovascular risk?
Lee JH; Engler MM
Prog Cardiovasc Nurs; 2009 Dec; 24(4):181-9. PubMed ID: 20002343
[TBL] [Abstract][Full Text] [Related]
6. [Lipoprotein associated phospholipase A2].
Rubinstein A; Izkhakov E
Harefuah; 2011 Feb; 150(2):136-40, 205. PubMed ID: 22164942
[TBL] [Abstract][Full Text] [Related]
7. Lipoprotein-associated phospholipase A2: an independent predictor of coronary artery disease events in primary and secondary prevention.
Anderson JL
Am J Cardiol; 2008 Jun; 101(12A):23F-33F. PubMed ID: 18549868
[TBL] [Abstract][Full Text] [Related]
8. Lipoprotein-associated phospholipase A2: a risk marker or a risk factor?
Lerman A; McConnell JP
Am J Cardiol; 2008 Jun; 101(12A):11F-22F. PubMed ID: 18549867
[TBL] [Abstract][Full Text] [Related]
9. The effect of darapladib on plasma lipoprotein-associated phospholipase A2 activity and cardiovascular biomarkers in patients with stable coronary heart disease or coronary heart disease risk equivalent: the results of a multicenter, randomized, double-blind, placebo-controlled study.
Mohler ER; Ballantyne CM; Davidson MH; Hanefeld M; Ruilope LM; Johnson JL; Zalewski A;
J Am Coll Cardiol; 2008 Apr; 51(17):1632-41. PubMed ID: 18436114
[TBL] [Abstract][Full Text] [Related]
10. Lipoprotein-associated phospholipase A2: role in atherosclerosis and utility as a cardiovascular biomarker.
Toth PP; McCullough PA; Wegner MS; Colley KJ
Expert Rev Cardiovasc Ther; 2010 Mar; 8(3):425-38. PubMed ID: 20222820
[TBL] [Abstract][Full Text] [Related]
11. Consensus panel recommendation for incorporating lipoprotein-associated phospholipase A2 testing into cardiovascular disease risk assessment guidelines.
Davidson MH; Corson MA; Alberts MJ; Anderson JL; Gorelick PB; Jones PH; Lerman A; McConnell JP; Weintraub HS
Am J Cardiol; 2008 Jun; 101(12A):51F-57F. PubMed ID: 18549872
[TBL] [Abstract][Full Text] [Related]
12. Utility of Lp-PLA2 in lipid-lowering therapy.
Racherla S; Arora R
Am J Ther; 2012 Mar; 19(2):115-20. PubMed ID: 20634673
[TBL] [Abstract][Full Text] [Related]
13. Lp-PLA₂- a novel risk factor for high-risk coronary and carotid artery disease.
Epps KC; Wilensky RL
J Intern Med; 2011 Jan; 269(1):94-106. PubMed ID: 21054587
[TBL] [Abstract][Full Text] [Related]
14. Effects of lifestyle counseling and combination lipid-modifying therapy on lipoprotein-associated phospholipase A2 mass concentration.
Reddy KJ; Singh M; Batsell RR; Bangit JR; Miraskar RA; Zaheer MS; Cockerham C; Wegner M
J Clin Lipidol; 2009 Aug; 3(4):275-80. PubMed ID: 21291824
[TBL] [Abstract][Full Text] [Related]
15. Metalloproteases 2 and 9, Lp-PLA(2) and lipoprotein profile in coronary patients.
Muzzio ML; Miksztowicz V; Brites F; Aguilar D; Repetto EM; Wikinski R; Tavella M; Schreier L; Berg GA
Arch Med Res; 2009 Jan; 40(1):48-53. PubMed ID: 19064127
[TBL] [Abstract][Full Text] [Related]
16. Diurnal variation in lipoprotein-associated phospholipase A(2) (Lp-PLA(2)).
Kaminsky LA; Ozemek C
Clin Biochem; 2012 Jun; 45(9):700-2. PubMed ID: 22465237
[TBL] [Abstract][Full Text] [Related]
17. Lipoprotein-associated phospholipase A2: an independent predictor of cardiovascular risk and a novel target for immunomodulation therapy.
Khakpour H; Frishman WH
Cardiol Rev; 2009; 17(5):222-9. PubMed ID: 19690473
[TBL] [Abstract][Full Text] [Related]
18. Effects of the direct lipoprotein-associated phospholipase A(2) inhibitor darapladib on human coronary atherosclerotic plaque.
Serruys PW; García-García HM; Buszman P; Erne P; Verheye S; Aschermann M; Duckers H; Bleie O; Dudek D; Bøtker HE; von Birgelen C; D'Amico D; Hutchinson T; Zambanini A; Mastik F; van Es GA; van der Steen AF; Vince DG; Ganz P; Hamm CW; Wijns W; Zalewski A;
Circulation; 2008 Sep; 118(11):1172-82. PubMed ID: 18765397
[TBL] [Abstract][Full Text] [Related]
19. Lipoprotein-associated phospholipase A2 as a biomarker of coronary heart disease and a therapeutic target.
Packard CJ
Curr Opin Cardiol; 2009 Jul; 24(4):358-63. PubMed ID: 19417639
[TBL] [Abstract][Full Text] [Related]
20. Lipoprotein-associated phospholipase A2 does not predict mortality or new ischaemic events in acute coronary syndrome patients.
Oldgren J; James SK; Siegbahn A; Wallentin L
Eur Heart J; 2007 Mar; 28(6):699-704. PubMed ID: 17314110
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
